Key facts

  • A world leader within diabetes and haemophilia
  • Sales totalled DKK 83.572 billion in 2013 (EUR 11.202 billion)
  • In 2013 total insulin market share of 48% and modern insulin market share 46%, measured by volume (Source IMS)
  • 38.436 full time employees at the end of 2013
  • Focus on core areas with large unmet medical needs: Diabetes care, haemophilia, growth hormone disorders and other biopharmaceuticals
  • Strong global commercial and manufacturing setup
  • Listed on Nasdaq Copenhagen and New York Stock Exchange